Stay updated on Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial
Sign up to get notified when there's something new on the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page.

Latest updates to the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe webpage has been updated to reflect a new phase II open-label study of nivolumab combined with ipilimumab and bicalutamide for HER2-negative metastatic or unresectable breast cancer, with changes in the study's collaborators and revision number. The previous goal of the protocol has been removed, indicating a shift in focus.SummaryDifference50%
- Check35 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, indicating a new release. Additionally, a date has been added, which may signify an important upcoming event or deadline.SummaryDifference0.2%
- Check64 days agoChange DetectedThe webpage has updated its date-related content, removing several past dates and adding new future dates, indicating a shift in the timeline of events or availability.SummaryDifference0.8%
- Check71 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check93 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page.